The European Medicines Agency's Committee for Medicinal Products for Human Use has endorsed the approval of Anoro, a combination of vilanterol and umeclidinium, as a treatment for chronic obstructive pulmonary disease. The drug was jointly developed by GlaxoSmithKline and Theravance. The committee also recommended the approval of umeclidinium, sold under the brand name Incruse, as a monotherapy for COPD.
EU panel supports approval of Anoro, Incruse for treatment of COPD
SmartBrief Job Listings for Health Care
|Senior Director, Biostatistics||
|Associate - Food and Drug||
Keller and Heckman LLP
|Senior Paralegal - Research & Development, and Medical||